滑膜肉瘤预后相关因素分析

目的 分析影响滑膜肉瘤患者预后的相关因素.方法 回顾性分析1997年9月至2008年9月就诊的66例滑膜肉瘤患者中52例获得随访的患者的临床资料.其中男性28例,女性24例;发病年龄11～71岁,均以无痛性肿块入院.通过随访了解肿瘤学预后,明确3、5年总体生存率及局部复发率.通过回顾病例,分析年龄、性别、肿瘤部位、肿瘤直径、外科边界、病理亚型、局部治疗方式、是否侵及骨与神经血管以及是否化疗9项因素对总体生存率的影响.利用Kaplan-Meier生存分析确定对生存有影响的单个因素,并通过Cox回归分析明确影响预后的独立危险因素.结果 52例患者获得随访,随访率78.8％;随访时间6 ～ 88个月,中位随访时间32个月.患者5年总体生存率为30.3％,局部复发率为32.7％,中位复发时间16个月.单因素分析结果提示:肿瘤直径＜5 cm、取得广泛外科边界、肿瘤位于四肢以及采取广泛切除联合局部放疗的患者预后较好(P＜0.05).多因素分析显示肿瘤直径,部位以及是否取得广泛外科边界是影响预后的独立危险因素.结论 肿瘤直径、部位以及是否取得广泛外科边界是影响预后的独立危险因素.     

骨的孤立性转移瘤的预后相关因素分析

[目的]分析骨的孤立性转移瘤预后相关因素,选择恰当的手术方式。[方法]2002年5月～2010年5月,共收治134例孤立性骨转移瘤患者,其中男76例,女58例,平均59岁。通过随访了解肿瘤学预后,明确1、3年总体生存率及局部复发率。通过回顾病例,分析年龄、性别、原发肿瘤类型、转移部位、有无病理骨折、有无内脏转移、外科边界以及诊断原发肿瘤至出现转移间隔时间8项因素对总体生存率的影响。利用Kaplan-Meier生存分析(log-rank检验)确定对生存率有影响的单个因素,并通过Cox回归进行多因素分析明确影响预后的独立危险因素。[结果]105例患者获得随访,随访率78.4%,中位随访时间32.4个月(3～80个月)。患者1、3年总体生存率和复发率分别为78.9%、40.7%和7.5%、23.8%,中位复发时间16个月。单因素分析结果提示:原发肿瘤为进展较慢的肾癌、甲状腺癌、乳腺癌、前列腺癌,行骨科手术时未出现其他脏器转移,取得广泛外科边界、无病理性骨折的患者预后较好(P<0.05)。多因素分析显示原发为进展较慢的肿瘤,行骨科手术时未出现其他脏器转移以及取得广泛外科边界是影响预后的独立危险因素。取得广泛外科边界同样是影响局部复发率的独立危险因素。[结论]原发肿瘤为进展较慢的肾癌、甲状腺癌、乳腺癌、前列腺癌,行骨科手术时未出现其他脏器转移以及取得广泛外科边界是影响预后的独立危险因素。     

原发肢体软组织肉瘤208例预后的影响因素分析

目的 探讨影响肢体软组织肉瘤预后的因素,特别是外科治疗对其预后的影响.方法 回顾性研究208例手术治疗的肢体软组织肉瘤患者,其中男性128例,女性80例,平均年龄46岁(9～98)岁.分析患者是否初治、肿瘤的大小(＜5 cm、5～10 crn、＞10 cm)、深度(深筋膜深层、浅层)、组织学分型(脂肪肉瘤、恶性纤维组织细胞瘤、滑膜肉瘤、纤维肉瘤、恶性神经鞘瘤、其他肿瘤)、病理分级(FNCLCC系统Ⅰ、Ⅱ、Ⅲ级)、外科边界(囊内切除、边缘切除、广泛切除、根治切除)以及辅助治疗等因素对患者预后的影响.结果 中位随访时间37.5个月(1.3 ～ 128.1个月),总体3年、5年生存率77％和75％;复发率28％和37％;转移率35％和43％.肿瘤大小、病理分级和术前是否有转移可以独立影响生存率(x2=18.813、24.849、21.107,均P＜0.05);是否为初治病例、组织学分型可以独立影响复发率(x2=21.915、12.192,P＜0.05);病理分级可以独立影响转移率(x2=7.714,P＜O.05).手术外科边界可以独立影响局部复发率和转移率(x2=19.610、9.272,P＜0.05).结论 外科边界独立影响局部复发率和远处转移率,从而间接影响生存率.尤其对无转移的初次治疗的软组织肉瘤,手术是首选方案,手术外科边界达到广泛切除或根治性切除将明显改善患者的预后.     

老年喉癌患者手术疗效及相关预后因素分析

目的 探讨老年喉癌患者手术疗效及相关预后因素分析.方法 回顾性分析110例老年喉癌患者的临床资料,选择10个临床因素,采用单因素分析及Cox风险模型,分析老年喉癌患者的预后影响因素.结果 110例患者1、3、5年生存率分别为98.2%、73.6%和54.5%.单因素结果提示：肿瘤原发部位、淋巴结转移、肿瘤大小、TNM分期、病理分级、治疗方式、年龄对患者预后影响有统计学意义（P ＜0.05）;多因素分析结果显示：肿瘤原发部位、TNM分期、淋巴结转移和治疗方式是影响喉癌预后的独立因素.结论 影响喉癌预后的独立因素是肿瘤原发部位、TNM分期、淋巴结转移和治疗方式,喉功能保全性手术是治疗老年喉癌的较为理想的方法,早期诊断是提高生存率的关键.     

基于SEER数据库的原发性肝血管肉瘤预后因素分析

目的分析原发性肝血管肉瘤的预后影响因素。方法从SEER数据库中筛选出290例1975～2016年间诊断为原发性肝血管肉瘤的病人资料,对其临床基线特征进行生存分析。结果年龄≥70岁、肿瘤直径85 mm、男性、远处转移、未行原发部位手术和未化疗是影响预后的独立危险因素(P0.05)。远处转移行原发部位手术组、无转移未行原发部位手术组、局部转移未行原发部位手术组和远处转移未行原发部位手术组病人是否化疗均具有生存差异(P0.05)。结论原发性肝血管肉瘤罕见且预后差,主要发生于老年男性,早期发现和诊断可提高生存率。原发部位手术和化疗可以改善预后,但无远处转移行原发部位手术治疗的病人继续行化疗的获益可能不明显。     

胃肠道来源卵巢转移瘤的手术治疗及预后

目的 探讨胃肠道卵巢转移瘤的治疗方法及预后因素.方法 回顾性分析110例胃肠道卵巢转移瘤患者的治疗、生存情况及预后因素.结果 全组患者中位年龄45岁.原发病灶位于胃82例,结直肠28例.全组中位总体生存期16.3个月,中位无进展生存期8.2个月,1、3、5年的生存率分别为68.4%、15.4%和2.5%.单因素分析结果显示,原发灶部位(P＜0.01)、转移灶范围(P＜0.01)、肿瘤细胞减灭术(P＜0.01)、腹腔化疗(P＜0.05)和卵巢转移瘤组织学类型(P＜0.05)是影响患者预后的主要因素,而年龄、月经史、腹水、不同疗程化疗与患者的预后无明显相关性(P＞0.05);多因素分析结果显示,原发灶部位(P＜0.01)、转移灶范围(P＜0.05)、肿瘤细胞减灭术(P＜0.01)是影响卵巢转移瘤患者预后的独立因素.结论 卵巢转移瘤的预后较差.在切除原发肿瘤的同时,积极行满意的肿瘤细胞减灭术有助于延长患者的生存时间.     

骨恶性纤维组织细胞瘤预后因素分析

目的 探讨影响骨恶性纤维组织细胞瘤生存率、局部复发和远处转移的危险因素.方法 1997年7月至2010年7月共有56例骨恶性纤维组织细胞瘤患者接受治疗.对年龄、性别、肿瘤部位、肿瘤大小等9项可能影响预后的因素进行回顾性单因素和多因素分析.结果 44例患者获得随访,平均随访时间33.3个月(2周～78个月).5年总体生存率为50.1%,局部复发率为40.9%,局部复发中位时间12个月(3～60个月),术后转移发生率27.5%(11/40),中位转移时间为6.5个月(2～23个月).单因素分析结果表明,性别、就诊情况(初治和复发)、肿瘤部位、外科边界以及肿瘤分期与生存率有相关性(P＜0.05),外科边界、肿瘤部位与局部复发有相关性(P＜0.05),侵犯重要血管神经(有或无)与远处转移有相关性(P＜0.05);多因素分析显示,外科边界、肿瘤分期是影响生存率的独立危险因素,外科边界是影响局部复发的独立危险因素.结论 外科边界、肿瘤分期是影响生存率的独立危险因素,外科边界是影响局部复发的独立危险因素.

Abstract：

Objective To study the risk factors related to the survival rate, recurrence and metastasis of malignant fibrous histiocytoma of bone.Methods From July 1997 and July 2010, 56 patients with malignant fibrous histiocytoma of bone were treated.Univariate and multivariate analysis were performed to determine the probable risk factors including gender, age, tumor location, tumor size and so on.Results Forty-four cases were followed up ranged from 2 weeks to 78 months ( medium 33.3).The 5-year overall survival rate was 50.1%, local reccurence rate 40.9% with a median time of 12 months (3 to 60 months)and metastatic rate 27.5% (11/40)with a median time of 6.5 months (2 to 23 months).Univariate analysis indicated that gender, condition of presentation ( primary case or recurrence case), tumor location, surgical margin and surgical stage were significantly related to survival rate ( P ＜ 0.05 ), and tumor location and surgical margin were related to local recurrence rate (P ＜ 0.05 ), and important vessel or nerve invasion was related to metastatic rate(P ＜ 0.05 ).Multivariate analysis showed that surgical margin and surgical stage were independent risk factors for survival rate, of which surgical margin was the independent risk factor for recurrence rate.Conclusions Surgical margin and surgical stage are independent risk factors for survival rate, of which surgical margin is the independent risk factor for recurrence rate.     

软组织恶性纤维组织细胞瘤的治疗策略和预后分析

目的 分析软组织恶性纤维组织细胞瘤的治疗策略及预后相关因素.方法 回顾性分析1999年12月至2010年10月收治的78例软组织恶性纤维组织细胞瘤患者的临床资料,并对性别、年龄、肿瘤部位、肿瘤大小等9项可能影响预后的因素进行统计学分析.结果 60例患者获得随访,随访时间6～131个月,平均35.5个月.l、3、5年总体生存率分别为84.9％、72.9％和56.9％.术后局部复发20例(33.3％),中位局部复发时间为11.5个月(1～72个月).术后转移9例(15.0％),中位转移时间为7个月(1～26个月).单因素分析表明,就诊情况(初治组或复发治疗组)、肿瘤大小和外科边界与生存率有相关性(均P ＜0.05),外科边界、放疗与局部复发有相关性(P =0.000、0.039),外科边界与远处转移有相关性;多因素分析显示,外科边界是影响生存率(P =0.002,OR=5.753,95％CI1.904～17.386)和局部复发(P=0.000,RR =0.044,95％CI0.010 ～0.188)的独立危险因素.结论 外科边界是影响生存率和局部复发的独立危险因素.采取以手术为主联合放疗的综合治疗,方能减少复发、提高生存率.     

99例骨肉瘤肺转移患者随访结果分析

目的 了解骨肉瘤肺转移的预后情况,分析影响预后的因素.方法 回顾2000年1月至2008年7月治疗的99例骨肉瘤肺转移患者的临床资料,并对其预后进行随访,随访时间13～91个月,平均24.45个月.其中男65例,女34例;确诊时年龄7～68岁,平均20.39岁.患者均接受原发部位肿瘤切除治疗,93例患者接受新辅助化疗,6例因经济原因而未行其他辅助治疗.16例患者在就诊时即存在肺转移;47例在接受治疗期间发现肺转移,36例在随访期间发生肺转移.就发病年龄、肺转移数目、肺转移发生时段、合并其他部位的转移、原发肿瘤对化疗的反应、肺转移治疗等有可能影响预后的因素进行统计学分析.结果 从确诊骨肉瘤到发现肺转移时间为0～74个月,平均9.05个月.患者确诊骨肉瘤后的中位生存时间为25个月;累计一年、两年及五年生存率分别为87.4%、56.8%、23.4%.单因素统计分析显示骨肉瘤肺转移影响生存的有效预后因素为肺转移发生的时段及针对肺转移病灶的治疗;多因素统计分析显示肺转移发生的时段是影响预后的独立因素.其他因素如发病年龄、肺转移数目、合并其他部位的转移、原发肿瘤对化疗的反应等不具有统计学意义.结论 转移发生较晚且积极干预的骨肉瘤患者可获得较好的预后.对肺转移瘤进行积极的手术切除和辅助化疗能有效延长骨肉瘤肺转移患者的生存时间.     

99例骨肉瘤肺转移患者随访结果分析

目的 了解骨肉瘤肺转移的预后情况,分析影响预后的因素.方法 回顾2000年1月至2008年7月治疗的99例骨肉瘤肺转移患者的临床资料,并对其预后进行随访,随访时间13～91个月,平均24.45个月.其中男65例,女34例;确诊时年龄7～68岁,平均20.39岁.患者均接受原发部位肿瘤切除治疗,93例患者接受新辅助化疗,6例因经济原因而未行其他辅助治疗.16例患者在就诊时即存在肺转移;47例在接受治疗期间发现肺转移,36例在随访期间发生肺转移.就发病年龄、肺转移数目、肺转移发生时段、合并其他部位的转移、原发肿瘤对化疗的反应、肺转移治疗等有可能影响预后的因素进行统计学分析.结果 从确诊骨肉瘤到发现肺转移时间为0～74个月,平均9.05个月.患者确诊骨肉瘤后的中位生存时间为25个月;累计一年、两年及五年生存率分别为87.4%、56.8%、23.4%.单因素统计分析显示骨肉瘤肺转移影响生存的有效预后因素为肺转移发生的时段及针对肺转移病灶的治疗;多因素统计分析显示肺转移发生的时段是影响预后的独立因素.其他因素如发病年龄、肺转移数目、合并其他部位的转移、原发肿瘤对化疗的反应等不具有统计学意义.结论 转移发生较晚且积极干预的骨肉瘤患者可获得较好的预后.对肺转移瘤进行积极的手术切除和辅助化疗能有效延长骨肉瘤肺转移患者的生存时间.     

Ⅲ期软组织肉瘤规范化治疗及预后的相关因素分析

目的 探讨对Ⅲ期软组织肉瘤规范化治疗的疗效及影响预后的因素.方法 对2003年1月至2006年1月收治的67例经同一临床路径治疗的Ⅲ期肢体软组织肉瘤患者进行回顾性分析,确立切缘类型、肿瘤大小、解剖深度、术后随访期间是否肺转移、是否接受新辅助化疗为影响因素,观察各影响因素对主要指标总生存(0S),次要指标无转移生存(DRFS)的影响及各切缘类型的复发率.结果 单因素分析显示肿瘤大小、解剖深度、转移出现时间与OS相关(P＜0.05);肿瘤大小、解剖深度与DRFS相关(P＜0.05).切缘类型、新辅助化疗与OS、DRFS无相关性.各切缘类型的复发率差异无统计学意义.结论 盲目扩大切除并不能使患者的局部控制及生存受益,同级别肉瘤的大小及解剖深度是影响预后的重要影响因素.术后化疗期间发生肺转移患者预后较差.新辅助化疗对患者的OS及DRFS的影响尚无定论.     

Prognostic factors in Ewing's sarcoma of the foot

The outcome of treatment and prognostic factors were reviewed in 36 patients who had Ewing's sarcoma of the foot. The tumor was most common in the calcaneus (19 patients) and metatarsals (15 patients). Age, levels of lactate dehydrogenase, degree of anemia, tumor volume, type of surgery, and radiotherapy were not related to prognosis. Females with pain for less than 6 months, fever, high levels of erythrocyte sedimentation rate, and high levels of alkaline phosphatase showed a tendency for a poorer prognosis. The only observed prognostic factors are tumor site and treatment. Patients treated with four-drug neoadjuvant chemotherapy had the best survival. Four patients with metastatic disease at diagnosis died. Fourteen of 32 patients (44%) with localized Ewing's sarcoma were continuously disease-free at an average followup of 7 years.     

Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome.

OBJECTIVE: To assess outcome and prognostic factors for survival of adults with Ewing's sarcoma/primitive neuroectodermal tumor (PNET). BACKGROUND: Ewing's sarcoma/PNET is a disease of childhood rarely seen in adults. Accordingly, there is a relative paucity of published literature pertaining to outcome for adults with this disease. METHODS: Between 1979 and 1996, 37 patients with newly diagnosed Ewing's sarcoma/PNET were evaluated and treated at the Adult Sarcoma Program at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Twenty-six patients had localized disease at presentation and 11 had metastatic disease. All but two patients received multiagent chemotherapy. Local treatment consisted of surgery (7 patients), surgery and radiation therapy (19), radiation therapy (6), or no local treatment (5). Median follow-up for living patients was 100 months (range 8 to 199). RESULTS: The 5-year survival rate for the group overall was 37%+/-9%. The 5-year local control rate was 85%+/-7%. Significant favorable predictors for survival on univariate analysis included localized disease at presentation, primary origin in bone, primary size <8 cm, and a favorable objective response to chemotherapy. Patients with localized disease had a 5-year survival rate of 49%+/-11% compared with 0% for those with metastatic disease at presentation. Multivariate analysis showed three significant independent predictors for death: metastatic disease at presentation, primary origin in extraosseous tissue versus bone, and age 26 years or older. CONCLUSION: Adult patients with Ewing's sarcoma/PNET at highest risk for death are those who are older than 26 years and have metastatic disease or an extraosseous primary tumor. The development of novel therapies should target these high-risk groups.     

Influence of the tumor site and histopathology after resection for non-colorectal non-neuroendocrine liver metastases. A single center experience

IntroductionIt remains unclear whether liver resection is justified in patients with non-colorectal non-neuroendocrine liver metastases (NCNNLM). A single-center study was conducted to analyse overall survival (OS), disease-free survival (DFS), and potential prognostic factors in patients with different types of NCNNLM.MethodA retrospective analysis of all patients who underwent liver resection of NCNNLM from January 2006 to July 2019 was performed.ResultsA total of 62 patients were analyzed. 82.3% presented metachronous metastases and 74.2% were unilobar. The most frequent primary tumor site (PTS) were breast (24.2%), urinary tract (19.4%), melanoma (12.9%), and pancreas (9.7%). The most frequent primary tumor pathologies were breast carcinoma (24.2%), non-breast adenocarcinoma (21%), melanoma (12.9%) and sarcoma (12.9%). The most frequent surgical procedure performed was minor hepatectomy (72.6%). R0 resection was achieved in 79.5% of cases. The major complications’ rate was 9.7% with a 90-day mortality rate of 1.6%. The 1, 3 and 5-year OS/DFS rate were 65%/28%, 45%/36% and 46%/28%, respectively. We identified the response to neoadjuvant therapy and PTS as possible prognostic factors for OS (P =0.06) and DFS (P =0.06) respectively.ConclusionBased on the results of our series, NCNNLM resection produces beneficial outcomes in terms of OS and DFS. PTS and the response to neoadjuvant therapy could be the main prognostic factors after resection.     

Ewing's sarcoma of the pelvis. Long-term survival and functional outcome

Fifty patients with Ewing's sarcoma of the pelvis were treated using a multidisciplinary approach; followup of surviving patients averaged 137 months (range, 40-276 months). The addition of surgical resection to the multidisciplinary treatment for all patients was associated with improved survival compared with survival of patients treated with chemotherapy and radiation therapy alone; the addition of surgery to the treatment regimen of 37 patients without metastases also was associated with improved survival. There were no significant differences between the surgical and nonsurgical groups in terms of tumor size, stage of disease, patient age, duration of symptoms before diagnosis, or anatomic site. Surgery was used more often in recently treated patients, but the year of diagnosis and treatment did not significantly affect overall survival, secondary to large confidence intervals. The Short Form-36 and the Musculoskeletal Tumor Society functional evaluation instruments showed a superior level of function in the nonsurgical group, but this difference was not statistically significant. There have been many advances in the treatment of patients with Ewing's sarcoma during the past 3 decades, resulting in improved survival for patients with Ewing's sarcoma of the pelvis. The addition of surgery significantly improved survival and did not show a significant difference in functional outcome.     

Osteosarcoma and Ewing's sarcoma--The most frequent malignant bone tumors in children--therapy and outcome

BACKGROUND: Osteosarcoma and Ewing's sarcoma are the most frequent malignant bone tumors in children and young adults with relatively poor overall survival rates. METHODS: Between January 1980 and December 1994, 175 children with osteosarcoma and 64 children with Ewing's sarcoma were treated at the author's institution. 22 children had synchronous metastases, 19 patients had a pathologic fracture. Both groups were treated systemically with chemotherapy regimens (COSS and CESS). Local therapy was amputation or tumor resection and endoprosthetic replacement or biological reconstruction with wide or radical resection margins. In case of Ewing's sarcoma in 35 patients postoperative radiation therapy was done. RESULTS: Five-year overall survival rate for osteosarcoma and Ewing's sarcoma patients is about 63 %, ten-year survival rate for osteosarcoma patients is 60.2 %, for Ewing's sarcoma patients 54.5 %. Prognostic factors significantly influencing overall survival rates are tumor response to chemotherapy (p values = 0.0056 and 0.013, respectively), surgical treatment with adequate resection margins (p value = 0.0001 for osteosarcoma patients) and development of postoperative metastases (p value = 0.0001 for both groups). CONCLUSION: For both groups of malignant bone tumors systemic chemotherapy as well as adequate surgical therapy are necessary to reduce the rates of local recurrences and to achieve better survival rates.     

Prognostic factors in patients treated with stereotactic image-guided robotic radiosurgery for brain metastases: a single-center retrospective analysis of 223 patients

In this retrospective study, we evaluated the overall survival (OS) and local control (LC) of brain metastases (BM) in patients treated with stereotactic radiosurgery (SRS). The scope was to identify host, tumor, and treatment factors predictive of LC and survival and define implications for clinical decisions. A total of 223 patients with 360 BM from various histologies treated with SRS alone or associated with whole brain radiotherapy (WBRT) in our institution between July 1, 2008 and August 31, 2013 were retrospectively reviewed. Among other prognostic factors, we had also evaluated retrospectively Karnofsky performance status scores (KPS) and graded prognostic assessment (GPA). Overall survival (OS) and local control (LC) were the primary endpoints. Kaplan-Meier and Cox proportional hazards models were used to estimate OS and LC and identify factors predictive of survival and local control. The median duration of follow-up time was 9 months (range 0.4–51 months). Median overall survival of all patients was 11 months. The median local control was 38 months. No statistical difference in terms of survival or LC between patients treated with SRS alone or associated with WBRT was found. On multivariate analysis, KPS was the only statistically significant predictor of OS (hazard ratio [HR] 2.53, p?=?0.006). On univariate analysis, KPS and GPA were significantly prognostic for survival. None of the host, tumor, or treatment factors analyzed in the univariate model factors were significantly associated with local failure.